Why the FDA rejected RP1: Inside the Melanoma Drug Setback

FDA rejected RP1

The FDA rejected RP1, a touted breakthrough for advanced melanoma, citing insufficient clinical evidence and lingering safety questions. Regulators demanded longer follow‑up, while the sponsor argued the data showed meaningful survival benefit.

FDA rejected RP1 over data gaps

“The decision reflects our commitment to patient safety,” a spokesperson said.

Analysts note the setback could ripple through Reuters-tracked pipelines, potentially delaying similar agents by ↓ 30%. The episode also revives discussion about the agency’s risk tolerance, a topic that resurfaced in recent nuclear policy debates. Stakeholders now await a revised submission, hoping to address the FDA’s concerns before the next review cycle.

Analysis by Elena Rostova (Socio-Economic Trends Analyst).